Transmissible spongiform encephalopathy future or investigational therapies

From Wikidoc - Reading time: 2 min

Transmissible spongiform encephalopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Transmissible spongiform encephalopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Neurocognitive Disorder Due to Prion Disease

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Transmissible spongiform encephalopathy future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Transmissible spongiform encephalopathy future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Transmissible spongiform encephalopathy future or investigational therapies

CDC on Transmissible spongiform encephalopathy future or investigational therapies

Transmissible spongiform encephalopathy future or investigational therapies in the news

Blogs on Transmissible spongiform encephalopathy future or investigational therapies

Directions to Hospitals Treating Transmissible spongiform encephalopathy

Risk calculators and risk factors for Transmissible spongiform encephalopathy future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Future or Investigational Therapies[edit | edit source]

Recent research from the University of Toronto and Caprion Pharmaceuticals have discovered one possible avenue which might lead to quicker diagnosis, a vaccine or possibly even treatment for prion diseases. The abnormally folded proteins which cause the disease have been found to expose a side chain of amino acids which the properly folded protein does not expose. Antibodies specifically coded to this side chain amino acid sequence have been found to stimulate an immune response to the abnormal prions and leave the normal proteins intact. [2]

Another idea involves using custom peptide sequences. Since some research suggests prions aggregate by forming beta barrel structures, work done in vitro has shown that peptides made up of beta barrel-incompatible amino acids can help break up accumulations of prion. Yet a third idea concerns genetic therapy, whereby the gene for encoding protease-resistant protein is considered to be an error in several species, and therefore something to be inhibited.

References[edit | edit source]

Template:WikiDoc Sources


Licensed under CC BY-SA 3.0 | Source: https://www.wikidoc.org/index.php/Transmissible_spongiform_encephalopathy_future_or_investigational_therapies
1 | Status: cached on August 02 2024 00:20:12
↧ Download this article as ZWI file
Encyclosphere.org EncycloReader is supported by the EncyclosphereKSF